Genital herpes counselling tool

Introduction

Genital herpes is caused by herpes simplex virus (HSV). It is a chronic viral infection that occurs frequently among sexually active individuals. The diagnosis can trigger significant psychological, social, relationship and sexual distress for those affected. Adjusting to having genital herpes is key to managing the infection successfully and reducing the risk of transmission.Footnote 1Footnote 2 Both the management of the infection and the counselling messages given to an individual will be informed by the type of genital herpes he or she may have — either HSV-1 or HSV-2, or both. Ideally, a clinical diagnosis of HSV would be confirmed by type-specific laboratory testing (e.g., viral culture or nucleic acid amplification test [NAAT]).Footnote 3Footnote 4Footnote 5 Type-specific serology may be useful under certain circumstances, but because those results are an indirect marker of HSV infection, they are more complex to interpret than a positive viral identification test.

Research attests to the value of counselling for those diagnosed with a sexually transmitted infection (STI) in relieving their distress, helping them manage the infection and reducing the risk of transmission.Footnote 6Footnote 7Footnote 8 Therefore, providing supportive counselling to help affected individuals understand and cope with the infection is a pivotal role for practitioners in any practice setting.Footnote 2Footnote 9Footnote 10

This tool aims to enhance practitioner comfort and skills in providing counselling to individuals diagnosed with genital herpes. It is complementary to the Genital herpes simplex virus (HSV) Infections chapter of the Canadian Guidelines on Sexually Transmitted Infections.

Impact of a genital herpes diagnosis

As a practitioner, you may encounter a variety of responses from individuals who receive a genital herpes diagnosis, ranging from indifference to devastation. Some may display strong emotions and anxiety due to how they perceive the infection and the stigma associated with it.

Common psychological, social and sexual distress reactions may include:

These emotional sequelae may deter individuals from seeking further care, disclosing their status to sexual partners, or even engaging fully in their everyday lives. For example, low self-esteem may decrease the feeling of desirability and adversely affects romantic and sexual relationships. Some feel they are no longer appealing or worthy of a loving relationship as a result of having the infection.Footnote 1Footnote 11Footnote 12

The goal of supportive counselling is to help individuals:

Approach to counselling

The counselling tool provides practitioners with best practice interventions and specific messages for individuals suspected of having genital herpes or for those diagnosed with genital herpes.

How a practitioner informs and counsels an individual with genital herpes often will influence the patient's long-term adjustment to the infection.Footnote 6Footnote 7Footnote 11Footnote 12 Explaining a positive HSV test result can be difficult, since many complex issues must be conveyed. Easing discomfort by first acknowledging it and then proceeding to educate the individual about the infection can greatly empower him or her to manage it effectively.

Take time to examine your own views about genital herpes. Become aware of any stigmatizing attitudes and beliefs that can undermine counselling efforts.

Key counselling activitiesFootnote 9Footnote 13Footnote 14

Pre-test counselling

Some individuals may be shocked and distressed by even the possibility of having genital herpes. A practitioner who suspects HSV infection at the time of testing should be prepared to provide basic information and initial counselling.

Counselling should be patient/client-centered and based on their particular situation/needs. Depending on their initial presentation, you may be faced with counselling acutely affected individuals/couples, those with chronically recurring lesions, or those who may have a one-time episode with no recurrence.

Emergency care clinicians should refer individuals to primary care clinicians for follow-up.

Provide print and online resources for additional support (such as the Genital Herpes factsheet produced by the Canadian AIDS Treatment Information Exchange [CATIE]) and include contact information for counsellors, local support groups, sexual health info lines or sexual health clinics.

Many individuals benefit more from learning about the chronic aspects of genital herpes after their acute illness resolves or their level of initial distress lowers. Therefore, a follow-up appointment is recommended to discuss coping mechanisms for longer term self-management.Footnote 15

Discussion points:

What it is

Natural history

Transmission

Prevention

Screening, testing & diagnosis

Approaches to treatment

Post-test counselling for positive test results

Once HSV type-specific test results are received, more detailed information can be provided in the follow-up visit.

Individuals will often have concerns about the frequency and severity of outbreaks, the origin of their infection, their current and future sexual relationships, their likelihood of transmitting the infection to others, and the impact on future childbearing. Practitioners should set aside dedicated time for counselling and/or refer to another patient-support service.

Partner notification for genital herpes is not required as a public health measure; however, you should encourage individuals to disclose their genital herpes status to their sexual partners as a way to decrease transmission. Depending on the history, the most recent partner(s), the current partner(s) and new partners should be advised. Former or current partners should be encouraged to talk with healthcare providers who can evaluate their risk and the need for an HSV type specific serology if no history of lesion or viral testing if they develop signs and symptoms.

The individual's past, current and future partner(s) may benefit from having an evaluation, receiving counselling, and having HSV type-specific serologic testing to assess their potential infectiousness to help prevent neonatal herpes and decrease the risk of herpes transmission to new partners. Doing so will help couples make informed decisions about the level of protection they want to adopt. Suggest this option to your patient or client and, if possible, offer a counselling session with his or her partner to assist with disclosure and choosing their specific preventive activities (refer to Prevention section in Discussion points, below).

In couples where an asymptomatic partner is diagnosed with HSV-2 infection using type-specific serology , he or she should receive the same counselling as those with symptomatic infection. Advise these individuals that clinical manifestations can occur within a yearFootnote 29 and they should return if/when lesions appear to allow for confirmatory testing using a culture or NAAT .

Some individuals may be too distressed to fully benefit from counselling at the time of getting their test result. Therefore, provide print and online resources for additional support (such as the Genital Herpes factsheet produced by the Canadian AIDS Treatment Information Exchange [CATIE]) and include contact information for counsellors, local support groups, sexual health info lines or sexual health clinics.

Discussion points:

Refer to the key counselling activities section for best practices.

About herpes

Natural history & recurrences

HSV-2 is the main cause of recurrent genital herpes. [Note to practitioner: substantial information should be conveyed to patients, so they understand clearly the very different natural courses of genital HSV-1 and HSV-2, with implications for symptomatic management, the potential for sexual transmission, and treatment, particularly suppressive therapy.]

Transmission

Prevention

HSV & HIV co-infection

Treatment

Disclosure and partner testing

It is strongly encouraged that you disclose your genital herpes status to your most recent, current and future sexual partner(s). Telling your sexual partner(s) about your herpes infection may be difficult or challenging, but it can also have beneficial outcomes. It is an important strategy to prevent the spread of the virus. It has been shown that disclosure of the herpes infection to sexual partner may reduce risk of transmission by approximately 50%.Footnote 48

[Note to practitioner:

Pregnancy

FAQs: Quick reference tool

Common questions raised by individuals following their genital herpes diagnosis are listed below, along with sample responses. This information is intended to give practitioners additional options for advising individuals following an HSV diagnosis.

Frequently asked questions/concerns Approaches and possible responses

This is awful. I don't know what to do.

Take an empathic approach and tailor messages to the individual's needs.

  • Reflective listening: "I understand you may be feeling upset and concerned about this information. Do you want to ask any questions?"
  • Reassure: "We know from hearing from others that this is a lot to handle and might be confusing and affect how you see yourself. You will likely go through a wide range of emotions."

Where did I get this? Who gave it to me?

  • "HSV-1 and HSV-2 can live in your body for a long time undetected/unrecognized – for months or years – so it's very difficult to know how long you've had the virus and who might have given it to you."

I was never with anyone who had sores or blisters.

  • "Genital herpes can be passed on from a person with no visible signs of the virus. It's common for people to be symptom-free but still contagious."

How often will I get outbreaks?

  • "The first time a person has symptoms is often the worst experience, and then over time the sores and blisters are less intense and less frequent."

Will I pass it to others?

  • "It's really important that you use condoms for sex with uninfected partners. If you and your partner(s) use condoms consistently and correctly, you can reduce (but not eliminate) the risk of transmitting genital herpes to your uninfected partner(s)."
  • "There's also antiviral drug therapy that's taken every day, which may help reduce the risk of transmission. You may want to think about this as an option."

Am I contagious every day?

  • "No, you're not. But you won't know what days you are, or are not, contagious except when you feel the prodromal symptoms or see blisters/sores. Asymptomatic shedding will occur randomly, which means there will be days when you are contagious but you won't feel or see any indication of shedding the virus."

What does this mean for my sex life?

  • "You can have a fulfilling sex life. HSV is a chronic infection, but you can adapt to having it. With time, you'll be able to self-manage and cope. Using condoms, disclosing your status, couple's counselling, ask your partner(s) to undergo testing, and considering the use of antiviral therapies will help you manage the risks of transmission to your partner(s)."
  • "There's support from other local resources available to you. You may benefit from working with a sex therapist, psychologist or couples counsellor. If you want, I can discuss what's available."

Do I have to tell my partner?

  • "It's really important to let your current sex partners know about your genital herpes and any future partners before you have sex."
  • "Try to be casual and direct. Let the topic come up in conversation. Just say you have the virus that causes genital herpes, and that it's very common and most people who have the virus don't know it. If you start with, 'I have really bad news for you…' or 'Don't freak out, but...', your partner will interpret it as something serious."
  • "Ask if your partner knows about it. Be prepared to talk about how the virus works and how you prevent it from spreading (e.g., condom use, oral suppressive antiviral medication, abstaining during outbreaks and prodromal phase). Explain that having genital herpes is only one small part of your life and that you deal with it."
  • "Disclosing your status is the right thing to do, so feel good about doing it."

I heard that medication for HSV can cause liver disease.

  • "The studies show that antiviral medications have been proven to be safe and effective to treat and suppress genital herpes over long periods of time."

I want to conceive; is it safe?

  • "Having genital herpes does not affect fertility. But you should tell your obstetrician or midwife about your or your partner's HSV infection, so you can prevent transmission of the virus to your newborn."

Acknowledgement

The Government of Canada would like to thank the following individuals for their contribution to the development of this tool.

References

Footnote 1

Steben M, Sénéchal K. Prévenir la transmission de l'herpès génital : une question de négociation ! Le Médecin du Québec 2006; 41(1):63-67.

Return to footnote 1 referrer

Footnote 2

Sankar P, Jones NL. To tell or not to tell: primary care patients' disclosure deliberations. Archives of Internal Medicine 2005; 165(20):2378-2383.

Return to footnote 2 referrer

Footnote 3

LeGoff J, Péré H, Bélec L. Diagnosis of genital herpes simplex virus infection in the clinical laboratory. Virology Journal 2014; 11(83).

Return to footnote 3 referrer

Footnote 4

Bernstein DI, Bellamy AR, Hook EW3, Levin MJ, Wald A, Ewell MG, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clinical Infectious Diseases 2013; 56(3):344-351.

Return to footnote 4 referrer

Footnote 5

Scoular A. Using the evidence base on genital herpes: Optimising the use of diagnostic tests and information provision. Sexually transmitted infections 2002; 78(3):160-165.

Return to footnote 5 referrer

Footnote 6

Fisher WA, Holtzapfel S. Principles and Practice of Sex Therapy. Fifth Edition ed. New York: Guilford; 2014.

Return to footnote 6 referrer

Footnote 7

Rietmeijer CA. Risk reduction counselling for prevention of sexually transmitted infections: how it works and how to make it work. Sexually transmitted infections 2007; 83(1):2-9.

Return to footnote 7 referrer

Footnote 8

Melville J, Sniffen S, Crosby R, Salazar L, Whittington W, Dithmer-Schreck D, et al. Psychosocial impact of serological diagnosis of herpes simplex virus type 2: A qualitative assessment. Sexually transmitted infections 2003; 79(4):280-285.

Return to footnote 8 referrer

Footnote 9

Romanowski B, Zdanowicz YM, Owens ST. In search of optimal genital herpes management and standard of care (INSIGHTS): doctors and patients perceptions of genital herpes. Sexually transmitted infections 2008; 84(1):51-56.

Return to footnote 9 referrer

Footnote 10

Sen P, Barton SE. Genital herpes and its management. British medical journal 2007; 334 (7602):1048-1052.

Return to footnote 10 referrer

Footnote 11

Green J, Wing C. Psychosocial issues in genital herpes management. Herpes 2004; 11(3):60-62.

Return to footnote 11 referrer

Footnote 12

Patel R. Supporting the patient with genital HSV infection. Herpes 2004; 11(3):87-92.

Return to footnote 12 referrer

Footnote 13

New Zealand Herpes Foundation: Professional Advisory Board of the Sexually Transmitted Infection Education Foundation. Guidelines for the Management of Genital Herpes in New Zealand, 11th Edition. 2015; Available at: http://www.herpes.org.nz/files/2914/6009/0632/genital-herpes-guidelines-2015.pdf. Accessed January/24, 2017.

Return to footnote 13 referrer

Footnote 14

World Health Organization. Training modules for the syndromic management of sexually transmitted infections, Second ed.: World Health Organization; 2007.

Return to footnote 14 referrer

Footnote 15

Centers for Disease Control and Prevention. 2015 Sexually Transmitted Diseases Treatment Guidelines: Genital HSV infections. 2015; Available at: https://www.cdc.gov/std/tg2015/herpes.htm. Accessed February/16, 2017.

Return to footnote 15 referrer

Footnote 16

Corey L, Wald A. Genital Herpes. In: Holmes K, editor. Sexually Transmitted Diseases: McGraw Hill Medical; 2008. p. 399-437.

Return to footnote 16 referrer

Footnote 17

Gnann JWJ, Whitley RJ. Genital Herpes. New England Journal of Medicine 2016;375(7):666-674.

Return to footnote 17 referrer

Footnote 18

American Sexual Health Association. The Herpes testing toolkit: A resource for healthcare providers. 2016; Available at: http://ashasexualhealth.org/pdfs/Herpes_Testing_Toolkit_2016.pdf, March 3, 2017.

Return to footnote 18 referrer

Footnote 19

Rotermann M, Langlois KA, Severini A, Totten S. Prevalence of Chlamydia trachomatis and herpes simplex virus type 2: Results from the 2009 to 2011 Canadian Health Measures Survey. Health Reports 2013; 24(4):10-15.

Return to footnote 19 referrer

Footnote 20

Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. New England Journal of Medicine 2000; 342(12):844-850.

Return to footnote 20 referrer

Footnote 21

Martin ET, Krantz E, Gottlieb SL, Magaret AS, Langenberg A, Stanberry L, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Archives of Internal Medicine 2009;169(13):1233-1240.

Return to footnote 21 referrer

Footnote 22

Wald A, Langenberg AG, Krantz E, Douglas JM, Handsfield HH, DiCarlo RP, et al. The relationship between condom use and herpes simplex virus acquisition. Annals of Internal Medicine 2005; 143(10):707-713.

Return to footnote 22 referrer

Footnote 23

Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. Journal of the American Medical Association 2001;285(24):3100-3106.

Return to footnote 23 referrer

Footnote 24

Steben M, Landry G, Cruz de Menezes R. La sérologie du virus Herpès simplex – trucs, attrapes et tromperies. Le Médecin du Québec 2016 10/2016:31-34.

Return to footnote 24 referrer

Footnote 25

Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. New England Journal of Medicine 2004; 350(1):11-20.

Return to footnote 25 referrer

Footnote 26

Hollier LM, Eppes C. Genital herpes: oral antiviral treatments. BMJ Clinical Evidence 2015; 04:1603.

Return to footnote 26 referrer

Footnote 27

Patel R, Tyring S, Strand A, Price MJ, Grant DM. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 1999 Dec;75(6):398-402.

Return to footnote 27 referrer

Footnote 28

Fife KH, Almekinder J, Ofner S. A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir. Sexually transmitted diseases 2007;34(5):297-301.

Return to footnote 28 referrer

Footnote 29

Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. New England Journal of Medicine 1999; 341(19):1432-1438.

Return to footnote 29 referrer

Footnote 30

Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med 1987 Jun 4;316(23):1444-1449.

Return to footnote 30 referrer

Footnote 31

Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994 Dec 1; 121(11):847-854.

Return to footnote 31 referrer

Footnote 32

Engelberg R, Carrell D, Krantz E, Corey L, Wald A. Natural history of genital herpes simplex virus type 1 infection. Sexually transmitted diseases 2003; 30(2):174-177.

Return to footnote 32 referrer

Footnote 33

Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. New England Journal of Medicine 1987; 316(23):1444-1449.

Return to footnote 33 referrer

Footnote 34

Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007 Dec 22; 370(9605):2127-2137.

Return to footnote 34 referrer

Footnote 35

Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983 Jun; 98(6):958-972.

Return to footnote 35 referrer

Footnote 36

Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clinical infectious diseases 1998; 26(3):554-555.

Return to footnote 36 referrer

Footnote 37

Sacks SL. The Truth about Herpes. Fourth Edition ed. Vancouver: Gordon Soules Book Publishers; 1997.

Return to footnote 37 referrer

Footnote 38

Blower S, Ma L. Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: treatment implications. Clinical Infectious Diseases 2004; 39(5):S240-S247.

Return to footnote 38 referrer

Footnote 39

Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. The Journal of infectious diseases 2002; 185(1):45-52.

Return to footnote 39 referrer

Footnote 40

Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006;20(1):73-83.

Return to footnote 40 referrer

Footnote 41

Corey L, Ashley R. Prevention of herpes simplex virus type 2 transmission with antiviral therapy. Herpes 2004; 11(3):170A-174A.

Return to footnote 41 referrer

Footnote 42

Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang ML, et al. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised open-label cross-over trials. Lancet 2012; 379(9816):641-647.

Return to footnote 42 referrer

Footnote 43

Smith CR, Pogany L, Auguste U, Steben M, Lau TTY. Does suppressive antiviral therapy for herpes simplex virus prevent transmission in an HIV-positive population? A systematic review. Canada communicable disease report = Relevé des maladies transmissibles au Canada 2016;42(2):37-44.

Return to footnote 43 referrer

Footnote 44

Sands-Lincoln M, Goldmann DR. Antiviral Drugs to Prevent Clinical Recurrence in Patients with Genital Herpes. American Journal of Medicine 2016; 129(12):1264-1266.

Return to footnote 44 referrer

Footnote 45

Lebrun-Vignes B, Bouzamondo A, Dupuy A, Guillaume J, Lechat P, Chosidow O. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. Journal of the American Academy of Dermatology 2007; 57(2):238-246.

Return to footnote 45 referrer

Footnote 46

Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370(9605):2127-2137.

Return to footnote 46 referrer

Footnote 47

Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med 2008; 168(11):1137.

Return to footnote 47 referrer

Footnote 48

Wald A, Krantz E, Selke S, Lairson E, Morrow RA, Zeh J. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis 2006 Jul 1; 194(1):42-52.

Return to footnote 48 referrer

Footnote 49

Kropp RY, Wong T, Cormier L, Ringrose A, Burton S, Embree JE, et al. Neonatal herpes simplex virus infections in Canada: results of a 3-year national prospective study. Pediatrics 2006 Jun; 117(6):1955-1962.

Return to footnote 49 referrer

Footnote 50

Money DM, Steben M. No. 208-Guidelines for the Management of Herpes Simplex Virus in Pregnancy. J Obstet Gynaecol Can 2017 Aug; 39(8):e199-e205.

Return to footnote 50 referrer

Page details

Date modified: